Albright’s disease, clinically known as McCune-Albright syndrome, is a rare, non-inherited genetic disorder that presents a classic triad of polyostotic fibrous dysplasia, café-au-lait cutaneous macules with characteristic jagged borders, and hyperfunctioning endocrinopathies, most commonly autonomous peripheral precocious puberty. Resulting from postzygotic somatic gain-of-function mutations in the GNAS gene, the condition creates a mosaic distribution of constitutively active cellular signaling that fundamentally disrupts skeletal integrity, dermatological patterning, and neuroendocrine homeostasis across organ systems.
Albright’s Disease
1. Concise Definition
Albright’s disease (predominantly designated in contemporary medical nomenclature as McCune-Albright syndrome) is a sporadic, mosaic developmental disorder caused by activating somatic mutations in the GNAS gene, which encodes the alpha subunit of the stimulatory G-protein (Gαs). The condition is conventionally characterized by the clinical triad of polyostotic fibrous dysplasia of bone, irregular hyperpigmented cutaneous patches known as café-au-lait macules, and autonomously functioning endocrinopathies, most frequently leading to gonadotropin-independent precocious puberty.
Because the disease arises from a postzygotic somatic mutation rather than a germline defect, it displays wide phenotypic variability determined by the precise timing of the mutational event during embryogenesis and the subsequent anatomical distribution of mutant cell lineages. Patients may exhibit anything from localized monostotic skeletal involvement and solitary hyperpigmented lesions to multi-organ endocrine hyperfunction, widespread osteolytic deformities, and substantial systemic morbidity.
2. Etymology & Linguistic Origin
The eponym “Albright’s disease” honors Fuller Albright (1900–1969), an American endocrinologist widely regarded as a founding figure of modern clinical endocrinology and bone metabolism. Albright described the condition in 1937, almost simultaneously with the American pediatrician Donovan James McCune (1902–1976), which led to the modern compound designation “McCune-Albright syndrome.” In early medical literature, the entity was occasionally categorized under descriptive nosological titles such as “osteitis fibrosa disseminata” or “fibrous osteodystrophy,” derived from the Greek osteon (bone), -itis (inflammation or disease process), and the Latin fibra (fiber) combined with the Greek trophe (nourishment or growth).
The linguistic development of the term reflects the evolution of clinical recognition: from a primarily orthopaedic curiosity characterized by aberrant fibro-osseous remodeling to a unified multisystem syndromic disorder defined by post-receptor endocrine signal transduction anomalies. As the molecular etiology was clarified in the early 1990s, the term evolved to encompass the broader concept of “Gαs-associated somatic mosaicism,” anchoring Albright’s original eponymous clinical observation within the rigorous framework of modern molecular genetics.
3. Pronunciation & Grammatical Form
Pronunciation: /ˈɔːl.braɪts dɪˈziːz/ (AWL-brayts dih-ZEEZ). In grammatical categorization, “Albright’s disease” functions as a proper noun phrase comprising a possessive eponym followed by a singular countable noun. Accepted variant designations include McCune-Albright syndrome (MAS), Albright syndrome, Albright-McCune-Sternberg syndrome, and osteitis fibrosa disseminata.
In standard academic discourse, the term is frequently used in the attributive form (e.g., “an Albright’s disease cohort,” “Albright-type fibrous dysplasia”) or replaced by the acronym MAS. When discussing specific manifestations, authors typically specify the dominant phenotype, differentiating classical triad cases from incomplete forms featuring monostotic involvement or solitary endocrinopathies.
4. Detailed Conceptual Explanation
The pathophysiology of Albright’s disease is grounded in the disruption of classic signal transduction cascades that govern cellular proliferation, differentiation, and hormone secretion. At the cellular level, the condition is driven by a missense mutation at the Arg201 (arginine-201) position—or rarely Gln227 (glutamine-227)—of the GNAS gene locus situated on chromosome 20q13.3. This amino acid substitution impairs the intrinsic GTPase activity of the Gαs protein subunit. Under ordinary physiological conditions, the Gαs protein acts as a molecular switch: when a seven-transmembrane G-protein-coupled receptor (GPCR) is stimulated by its cognate ligand (such as parathyroid hormone, thyroid-stimulating hormone, luteinizing hormone, or adrenocorticotropic hormone), Gαs binds guanosine triphosphate (GTP) and activates adenylyl cyclase, driving the conversion of adenosine triphosphate (ATP) to cyclic adenosine monophosphate (cyclic AMP).
Intrinsic GTPase activity typically hydrolyzes GTP back to guanosine diphosphate (GDP), resetting the system to an inactive baseline. In Albright’s disease, the loss of GTP hydrolysis locks Gαs in an unabated, constitutively active state. The intracellular concentration of cAMP escalates independently of extracellular ligand binding, which leads to chronic hyperactivation of protein kinase A (PKA) and down-stream transcription factors. In osteoprogenitor cells, sustained PKA signaling prevents regular terminal differentiation into mature osteocytes, driving the overproduction of abnormal, immature, woven bone embedded within an abundant fibrous connective stroma. This process results in the hallmark lesions of fibrous dysplasia, leaving the structural skeleton brittle, prone to microfractures, pathologically deformed, and metabolically active.
In cutaneous melanocytes, elevated intracellular cAMP mimics persistent melanocyte-stimulating hormone (MSH) receptor activation. This leads to hypermelanogenesis without cellular hyperplasia, producing the classical irregular café-au-lait macules. In endocrine tissues, continuous Gαs activation produces autonomous hypersecretion: follicular cells of the ovary produce estrogen without follicle-stimulating hormone (FSH) stimulation, thyroid follicular cells produce thyroxine independently of thyroid-stimulating hormone (TSH), somatotroph cells of the pituitary hypersecrete growth hormone (GH), and adrenocortical cells overproduce cortisol independent of ACTH. Because embryonic survival requires non-mutant cells, Albright’s disease is invariably mosaic; a constitutional, generalized germline mutation of this type is thought to be lethal in early embryogenesis.
The spatial and tissue distribution of the mutant clone is determined early during the blastocyst stage. If the mutational event occurs very early, mutant daughter cells populate ectodermal, mesodermal, and endodermal lineages, producing the full classic triad alongside rare hepatic, cardiac, or gastrointestinal involvement. If the mutation occurs later in gastrulation or organogenesis, the disease remains localized, potentially presenting solely as monostotic fibrous dysplasia or an isolated autonomous ovarian cyst. The clinical severity of Albright’s disease is therefore not determined by family history or heritable risk, but by the temporal timing and anatomical migration of the postzygotic mutant lineage.
5. Historical Development
The clinical recognition of Albright’s disease developed during an era of significant growth in metabolic endocrinology throughout the early to mid-twentieth century. In 1936, Donovan James McCune presented a clinical paper describing a female pediatric patient exhibiting localized skeletal deformities, unusual cutaneous hyperpigmentation, and autonomous sexual precocity. In May 1937, Fuller Albright and colleagues published their seminal paper in the New England Journal of Medicine entitled “Syndrome characterized by osteitis fibrosa disseminata, areas of pigmentation and endocrine dysfunction, with precocious puberty in females.” Albright documented five cases, carefully distinguishing the entity from generalized osteitis fibrosa cystica secondary to primary hyperparathyroidism, which had been characterized earlier by Friedrich Daniel von Recklinghausen.
Throughout the mid-20th century, investigators such as Charles E. Dent and others explored the natural history of the disorder, debating whether the primary driver was a central hypothalamic abnormality or an intrinsic peripheral defect of the end-organ tissues. The autonomous nature of the endocrinopathies—highlighted by suppressed pituitary gonadotropins alongside elevated peripheral estradiol in young girls—gradually shifted scientific consensus toward an intrinsic peripheral receptor or post-receptor mechanism.
A major breakthrough occurred in 1991 when Lee S. Weinstein and colleagues at the National Institutes of Health (NIH) sequenced the GNAS gene in patients with McCune-Albright syndrome. They identified specific missense point mutations within exon 8 and exon 9 that replaced arginine-201 with histidine or cysteine, pinpointing the precise molecular basis of constitutive Gαs activation. Over subsequent decades, long-term observational registries led by investigators such as Michael T. Collins and Alison M. Boyce documented the extensive natural history, skeletal burden scores, and metabolic complications of the disease, establishing systematic clinical diagnostic criteria and multi-specialty treatment guidelines.
6. Theoretical Foundations
Albright’s disease serves as a foundational archetype in several major fields of biological and medical theory, particularly cellular signaling, genetic mosaicism, and developmental biology. In receptor pharmacology, the condition is one of the clearest clinical illustrations of receptor-independent intracellular signaling. Conventional pharmacological models focus on ligand-receptor interactions initiating intracellular cascades; Albright’s disease demonstrates that when intracellular transducers are constitutively activated downstream, the entire upstream regulatory system loses control over cellular behavior.
In human genetics, Albright’s disease established the fundamental clinical model of human somatic mosaicism. Prior to its molecular elucidation, variable clinical presentations within non-Mendelian disorders often puzzled geneticists. The conceptual demonstration that somatic mutations occurring post-fertilization generate variable distributions of mutant versus wild-type cell lineages provided a mechanistic framework that explains phenotypic variability, asymmetric anatomical distribution, and the absence of vertical transmission from affected parents to offspring.
Furthermore, the disorder intersects with modern concepts of bone biology, specifically the Wnt/β-catenin and RANK/RANKL signaling axes. Constitutively active cAMP signaling in stromal progenitor cells dramatically elevates the local secretion of receptor activator of nuclear factor-κB ligand (RANKL) while suppressing osteoprotegerin (OPG), generating high rates of osteoclast recruitment and osteolytic bone resorption. This mechanistic insight shifted the therapeutic paradigm from passive observation to the targeted modulation of osteoclast-mediated bone breakdown using bisphosphonates and monoclonal RANKL inhibitors.
7. Key Components, Types & Dimensions
The clinical spectrum of Albright’s disease spans multiple organ systems, with severity shaped by the mosaic distribution of mutated cells:
- Fibrous Dysplasia (FD): Skeletal lesions where normal bone marrow is replaced by fibro-osseous connective tissue containing poorly organized, irregular trabeculae of immature woven bone. FD can be monostotic (confined to a single bone) or polyostotic (affecting multiple skeletal sites). Craniofacial involvement can cause facial asymmetry, visual impairment through optic nerve canal encasement, hearing loss, and malocclusion, while femoral lesions frequently yield the classic “shepherd’s crook” varus deformity and recurrent pathological fractures.
- Café-au-Lait Macules: Hyperpigmented cutaneous patches with jagged, irregular borders often likened to the “Coast of Maine,” in contrast to the smooth “Coast of California” borders seen in neurofibromatosis type 1. These macules typically follow the embryological lines of Blaschko, respect the anatomical midline, and are most commonly found on the back, buttocks, and posterior neck.
- Autonomous Precocious Puberty: The most prevalent endocrinopathy, predominantly affecting females. It is driven by the intermittent formation of unilateral estrogen-producing ovarian cysts independent of pituitary gonadotropins (FSH and LH). Clinically, this manifests as vaginal bleeding, breast budding, accelerated linear growth, and advanced skeletal maturation. In males, gonadotropin-independent precocious puberty is less common and characterized by autonomous Leydig cell hyperplasia.
- Hyperthyroidism: Encountered in roughly one-third to one-half of patients, driven by autonomous hyperfunctioning thyroid nodules. It presents with suppressed TSH, elevated free T3 and T4, resting tachycardia, muscle weakness, and accelerated bone remodeling.
- Growth Hormone Excess: Present in approximately 20% of cases, arising from pituitary somatotroph hyperplasia or adenoma. When untreated, persistent GH and IGF-1 elevation accelerates the expansion of craniofacial fibrous dysplasia, dramatically increasing the risk of optic nerve compression and blindness.
- Hypercortisolism (Cushing’s Syndrome): A rare manifestation typically appearing in early infancy as a result of autonomous adrenocortical hyperplasia. It carries elevated morbidity and frequently requires urgent surgical adrenalectomy or targeted medical management.
- FGF23-Mediated Hypophosphatemia: Chronic renal phosphate wasting caused by excessive production of fibroblast growth factor 23 (FGF23) directly by the dysplastic bone tissue, leading to hypophosphatemic rickets and osteomalacia that compounds skeletal weakness.
8. Examples & Illustrative Cases
To understand how Albright’s disease manifests in practice, consider two representative clinical vignettes that reflect its spectrum of presentation:
Case 1: Severe Classical Triad in a Female Child
A three-year-old girl is evaluated by a pediatric endocrinologist after experiencing two discrete episodes of painless vaginal spotting. Physical examination reveals unilateral, jagged-edged café-au-lait pigmentation extending across her right gluteal region and terminating precisely at the spinal midline. Skeletal imaging reveals polyostotic fibrous dysplasia involving the right femur and ipsilateral hemipelvis, showing typical “ground-glass” expansile lesions. Pelvic ultrasonography confirms a solitary 3.5 cm autonomous ovarian cyst on the right ovary with a thickened endometrial stripe, while serum evaluations show elevated estradiol levels alongside suppressed baseline FSH and LH. This presentation represents the classical complete triad of McCune-Albright syndrome, managed through peripheral aromatase inhibition and orthopaedic monitoring.
Case 2: Craniofacial Fibrous Dysplasia with Growth Hormone Excess
A twelve-year-old male presents with worsening asymmetric enlargement of the left mandible, progressive facial asymmetry, and unilateral nasal congestion. A skull CT scan reveals expansive, dense, fibro-osseous ground-glass lesions involving the sphenoid, ethmoid, and maxillary bones, with significant remodeling around the left optic canal. Biochemical screening reveals an elevated insulin-like growth factor 1 (IGF-1) level and a failure of GH to suppress during an oral glucose tolerance test. Detailed skin examination reveals a faint, irregular café-au-lait patch over the posterior cervical region that was previously overlooked. Treatment focuses on stabilizing GH hypersecretion using somatostatin analogs or pegvisomant to prevent accelerated expansion of the craniofacial lesions and preserve visual acuity.
9. Measurement & Assessment
The diagnostic evaluation of Albright’s disease relies primarily on comprehensive clinical, radiological, and biochemical assessments, supplemented by targeted molecular analyses where appropriate. The diagnostic threshold is met when at least two classic features of the triad (polyostotic fibrous dysplasia, Coast of Maine café-au-lait macules, and hyperfunctioning endocrinopathy) are present. In patients with monostotic fibrous dysplasia or an isolated endocrinopathy, identification of the pathogenic GNAS mutation in affected tissue establishes the diagnosis.
Radiological imaging is central to evaluating skeletal involvement. Plain radiography identifies characteristic radiolucent, hazy, “ground-glass” bone matrix patterns with endosteal scalloping and cortical thinning. Whole-body 18F-sodium fluoride (18F-NaF) PET/CT or 99mTc-methylene diphosphonate (MDP) bone scintigraphy is the gold standard for mapping the full extent of skeletal disease, yielding a validated skeletal burden score (SBS). Craniofacial lesions are best evaluated using non-contrast high-resolution computed tomography (CT) to assess the neural foramina, optic canals, and base of the skull.
Biochemical assessment requires a systematic endocrine profile. Clinicians monitor serum alkaline phosphatase and osteocalcin as markers of skeletal turnover. Endocrine screening includes early morning estradiol, testosterone, LH, and FSH (with GnRH stimulation testing to distinguish peripheral from central precocious puberty), free T4, total T3, TSH, serum IGF-1, prolactin, fasting morning cortisol, and ACTH. To monitor phosphate homeostasis, clinicians measure fasting serum phosphate, calcium, and tubular reabsorption of phosphate per unit of glomerular filtration rate (TmP/GFR), alongside serum intact FGF23 levels.
Confirmatory molecular genetic testing of peripheral blood leukocytes typically has a low yield due to mosaicism, often missing the localized mutation. High-sensitivity techniques—such as droplet digital PCR (ddPCR) or next-generation deep sequencing of DNA extracted from affected tissue (e.g., dysplastic bone biopsies, surgical endocrine specimens, or hyperpigmented skin scrapings)—significantly increase diagnostic sensitivity, detecting low-frequency mosaicism that standard Sanger sequencing can miss.
10. Applications & Practical Significance
The clinical management of Albright’s disease requires a multidisciplinary framework that spans pediatric and adult endocrinology, orthopaedic surgery, craniofacial surgery, ophthalmology, and physical rehabilitation. From a therapeutic perspective, early detection of autonomous precocious puberty is essential to prevent premature epiphyseal plate fusion, preserve final adult height, and reduce psychological distress associated with early sexual maturation. The standard pharmacological approach utilizes third-generation aromatase inhibitors (such as letrozole or anastrozole) to suppress estrogen synthesis, sometimes combined with selective estrogen receptor modulators (tamoxifen) or estrogen antagonists (fulvestrant). If advanced bone age triggers secondary, central precocious puberty, GnRH agonists are introduced.
In managing fibrous dysplasia, orthopaedic strategies focus on preserving mobility and preventing deformities. Prophylactic intramedullary rodding of weight-bearing long bones is preferred over conventional plate-and-screw fixation or simple bone grafting, as dysplastic tissue resorbs cortical bone grafts over time. Anti-resorptive therapies, including intravenous bisphosphonates (pamidronate or zoledronic acid) and the human monoclonal anti-RANKL antibody denosumab, reduce bone turnover markers and manage chronic bone pain. However, clinicians monitor carefully for potential rebound hypercalcemia and hypophosphatemia after discontinuing denosumab.
Screening for autonomous thyroid and growth hormone hypersecretion is essential, as even mild, subclinical excess accelerates FD lesion progression. Hyperthyroidism is treated primarily with antithyroid medications (methimazole) or definitive total thyroidectomy, while radioactive iodine ablation is generally used with caution due to theoretical risks of secondary malignant transformation within nearby dysplastic bone. Growth hormone excess is treated with somatostatin receptor ligands (octreotide, lanreotide) and growth hormone receptor antagonists (pegvisomant); primary pituitary radiotherapy is rarely used due to the risk of sarcomatous transformation in irradiated dysplastic craniofacial bone.
11. Research & Empirical Evidence
Longitudinal natural history studies conducted primarily by the National Institute of Dental and Craniofacial Research (NIDCR) and the NIH Clinical Center have provided detailed insights into the clinical course of Albright’s disease. A landmark study by Collins et al. (2001) tracked skeletal disease over several decades, showing that the total skeletal burden of fibrous dysplasia typically establishes its anatomical footprint early in childhood, with most lesions developing by age ten, after which lesions expand within their established margins rather than spreading to unaffected skeletal regions.
Research by Boyce et al. (2012) focused on FGF23-mediated hypophosphatemia, demonstrating that overproduction of FGF23 directly by early fibro-osseous cells correlates with the total volumetric burden of fibrous dysplasia. This work showed that elevated circulating FGF23 levels predict fracture risk, progressive spinal deformities, and severe bone pain. These findings established serum phosphate and TmP/GFR monitoring as standard components of routine clinical care, with oral phosphate supplementation and active vitamin D (calcitriol) introduced when hypophosphatemic osteomalacia develops.
Recent clinical trials have evaluated targeted biologic therapies for skeletal manifestations. A phase II study by de Castro et al. (2019) demonstrated that denosumab substantially reduced bone turnover markers, relieved chronic bone pain, and decreased the expansion of giant-cell-rich lesions in patients with severe, refractory fibrous dysplasia. However, the study also identified a risk of marked rebound osteoclast activity and severe hypercalcemia following treatment cessation, highlighting the need for structured tapering protocols. Ongoing studies are exploring small-molecule inhibitors of PKA and targeted Gαs signaling modulators designed to address the underlying cellular defect directly.
12. Cultural & Cross-Cultural Considerations
Because Albright’s disease arises from spontaneous postzygotic mutations without familial inheritance, its incidence is uniform across diverse geographic regions, ethnic groups, and cultural backgrounds. The estimated prevalence ranges from 1 in 100,000 to 1 in 1,000,000 individuals globally, with equal frequency across genders, though females are often diagnosed earlier due to obvious clinical signs of precocious vaginal bleeding.
Despite its uniform biological incidence, disparities exist in access to specialized care, molecular testing, and multidisciplinary clinical teams. In lower-resource regions, autonomous precocious puberty can be mistaken for central precocious puberty or intracranial neoplasms, leading to inappropriate neuroimaging or ineffective therapies. Similarly, expansive craniofacial fibrous dysplasia may be misclassified as osteosarcoma or ameloblastoma, resulting in unnecessary, disfiguring surgical resections that contrast with conservative, functional approaches practiced at major referral centers.
Cultural perceptions of visible facial asymmetries, short stature, and early sexual development can have significant psychosocial impacts on affected children and their families. Pediatric patients often report challenges related to social stigmatization and body image, particularly when facial lesions expand during adolescence. These considerations highlight the importance of integrating psychological support alongside medical, orthopaedic, and surgical interventions.
13. Criticisms, Debates & Limitations
Managing Albright’s disease involves several longstanding clinical debates, particularly regarding craniofacial surgery, medical bone therapy, and malignancy risks. A key historical debate centered on prophylactic surgical decompression of the optic canal in patients whose craniofacial fibrous dysplasia surrounds the optic nerve without causing symptoms. Early surgical practices often favored routine decompression to prevent blindness. However, prospective longitudinal studies demonstrated that encasement of the optic canal rarely leads to vision loss unless accompanied by untreated growth hormone excess. Given that prophylactic surgery carried risks of iatrogenic nerve injury, clinical guidelines shifted to prioritize watchful waiting with routine visual testing, reserving surgical intervention for cases of documented, acute visual deterioration.
The role of bisphosphonates in fibrous dysplasia remains another area of discussion. While initial uncontrolled trials suggested bisphosphonates increased bone density within dysplastic lesions, subsequent randomized placebo-controlled trials indicated that although intravenous bisphosphonates often relieve bone pain, they do not consistently alter underlying lesion progression or repair cortical bone integrity. This distinction between symptomatic pain relief and disease-modifying efficacy has led to more measured clinical expectations.
A final clinical concern involves the risk of secondary malignant transformation. Although fibrous dysplasia is benign, osteosarcoma, fibrosarcoma, or chondrosarcoma can arise within dysplastic lesions in less than 1% of cases. Historically, therapeutic radiation directed at craniofacial bones significantly increased this transformation risk, which led to a near-total avoidance of radiotherapy for these patients. Ongoing discussions also evaluate whether long-term suppression of bone remodeling with potent antiresorptives might influence cellular transformation risks over several decades, reinforcing the need for lifelong clinical surveillance.
14. Related Terms & Distinctions
Several conditions share individual clinical features with Albright’s disease, requiring careful differential diagnosis:
- Neurofibromatosis Type 1 (NF1): Shares the presence of café-au-lait macules, but lesions in NF1 typically feature smooth, regular margins (“Coast of California”), axillary or inguinal freckling (Crowe sign), and neurofibromas. NF1 is an autosomal dominant disorder caused by germline mutations in the NF1 gene, lacking the characteristic polyostotic fibrous dysplasia and autonomous endocrinopathies seen in Albright’s disease.
- Monostotic and Polyostotic Fibrous Dysplasia (isolated): Represents the isolated skeletal presentation of somatic GNAS mosaicism without cutaneous hyperpigmentation or hyperfunctioning endocrinopathies.
- Mazabraud Syndrome: A rare variant of fibrous dysplasia characterized by the development of multiple intramuscular myxomas, which may occur with or without other features of McCune-Albright syndrome.
- Jaffé-Lichtenstein Syndrome: A historical term previously used for polyostotic fibrous dysplasia with café-au-lait pigmentation in the absence of endocrine hyperfunction. It is now understood as part of the broader clinical spectrum of GNAS somatic mosaicism.
- Primary Hyperparathyroidism: Can cause widespread osteolytic bone changes (osteitis fibrosa cystica). However, it is driven by excessive parathyroid hormone from a parathyroid adenoma or hyperplasia and lacks café-au-lait pigmentation, autonomous ovarian cysts, and GNAS mutations.
15. Summary / Key Takeaways
Albright’s disease is a complex, multisystem disorder caused by early postzygotic gain-of-function somatic mutations in the GNAS gene, resulting in constitutive activation of the Gαs signaling protein and unregulated intracellular cAMP production. The classic clinical presentation includes polyostotic fibrous dysplasia of bone, irregular “Coast of Maine” café-au-lait skin lesions, and autonomous hyperfunctioning endocrinopathies, such as peripheral precocious puberty, hyperthyroidism, growth hormone excess, and hypophosphatemic rickets.
Because the underlying mutation is mosaic and not passed through the germline, the clinical expression of Albright’s disease varies widely based on the embryonic timing and anatomical distribution of the mutated cell lineage. Modern patient care relies on coordinated, multidisciplinary management focused on controlling endocrine hypersecretion, stabilizing skeletal lesions, managing bone pain, and monitoring craniofacial risks, all while supporting long-term quality of life through individualized, evidence-based care.
References
- Boyce, A. M., & Collins, M. T. (2020). Fibrous Dysplasia/McCune-Albright Syndrome. In M. P. Adam, G. M. Mirzaa, R. A. Pagon, et al. (Eds.), GeneReviews®. University of Washington, Seattle. https://www.ncbi.nlm.nih.gov/books/NBK174564/
- Collins, M. T., Singer, F. R., & Eugster, E. (2012). McCune-Albright syndrome and the GNAS oncogene. The Journal of Clinical Endocrinology & Metabolism, 97(4), 1094–1102. https://doi.org/10.1210/jc.2011-3006
- de Castro, L. F., Bhattacharyya, N., Estrada, E. L., et al. (2019). Denosumab treatment for fibrous dysplasia of bone: A phase II clinical trial. Journal of Bone and Mineral Research, 34(10), 1805–1817. https://doi.org/10.1002/jbmr.3813
- Javaid, M. K., Boyce, A. M., Appelman-Dijkstra, N., et al. (2019). Best practice management guidelines for fibrous dysplasia/McCune-Albright syndrome: A consensus statement from the FD/MAS international consortium. Orphanet Journal of Rare Diseases, 14(1), 139. https://doi.org/10.1186/s13023-019-1102-9
- Weinstein, L. S., Shenker, A., Gejman, P. V., Merino, M. J., Friedman, E., & Spiegel, A. M. (1991). Activating mutations of the stimulatory G protein in the McCune-Albright syndrome. New England Journal of Medicine, 325(24), 1688–1695. https://doi.org/10.1056/NEJM199112123252403